Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 1997

View Archived Issues

New alpha1-adrenoceptor antagonist evaluated

Medtronic and Somnus to codevelop snoring and sleep apnea therapy

Allelix adds two neuropharmaceutical development programs in Q2 1997

Allergan: Q1 1997 highlights

Genentech: Q1 1997 highlights

Warner-Lambert reaffirms goal of average EPS growth in mid-teens for balance of century

Neurotrophic/neuroprotective agents described by Synthelabo

Allergan claims prostaglandin derivatives with vasodilating activity

Substance P and bradykinin antagonists from Kyowa Hakko

MiniMed and Trimeris collaborate to deliver HIV therapy

Roussel Uclaf claims new cephalosporins

NovaDx discovers osteoporosis drug opportunities

Biosource awarded grant for human therapeutic protein production

Antitumor agents described by Sagami

PRIZM announces gene targeting results

BTG licenses Campath-1H to LeukoSite

Shareholder meeting set for Vaxel/Zynaxis merger

Antiarthritic activity and mechanism of action of mercaptoethylguanidine

CoCensys discovers potent, water-soluble allosteric modulators of GABA-A receptor

Titan issued U.S. patent for cancer vaccine

Lilly prepares water-soluble echinocandin antifungal agents

Mylan Laboratories's Acyclovir receives FDA approval

Novel marine antioxidant described by UNC researchers

Bioniche reports positive clinical results for Regressin

Amino-ketones from Roche found to lower cholesterol levels in animals

Mimetix initiates clinical trial with injectable form of naproxen

Potent, selective beta3-agonist from Merck & Co.

Demeter reports results with Peptidyl MIM in animal model of prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...